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A B S T R A C T
Theophylline (TP) is a very well established orally or intravenously delivered antiasthma
drug with many beneficial effects. This study aims to improve asthma treatment by creat-
ing a dry powder inhalable (DPI) formulation ofTP to be delivered directly to the lung, avoiding
the side effects associated with conventional oral delivery. The DPI TP formulation was in-
vestigated for its physico-chemical characteristics using scanning electron microscopy, laser
diffraction, thermal analysis and dynamic vapour sorption. Furthermore, aerosol perfor-
mance was assessed using the Multi Stage Liquid Impinger (MSLI). In addition, a Calu-3 cell
transport assay was conducted in vitro using a modified ACI to study the impact of the DPI
formulation on lung epithelial cells. Results showed DPI TP to be physico-chemically stable
and of an aerodynamic size suitable for lung delivery.The aerosolisation performance analy-
sis showed the TP DPI formulation to have a fine particle fraction of 29.70 ± 2.59% (P < 0.05)
for the TP formulation containing 1.0% (w/w) sodium stearate, the most efficient for
aerosolisation. Regarding the deposition of TP DPI on Calu-3 cells using the modified ACI,
results demonstrated that 56.14 ± 7.62% of the total TP deposited (13.07 ± 1.69 μg) was trans-
ported across the Calu-3 monolayer over 180 min following deposition, while 37.05 ± 12.62%
of the deposited TP was retained in the cells. This could be due to the presence of sodium
stearate in the current formulation that increased its lipophilicity. A DPI formulation of TP
was developed that was shown to be suitable for inhalation.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
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Theophylline (TP) is a well established orally or intrave-
nously delivered antiasthma drug [1–5]. The main drawbacks
of this active pharmaceutical ingredient (API) are related to its
narrow therapeutic index and several side effects, i.e. nausea,
headache, dizziness and vomiting [2,6]. Increasing evidence
shows that it has significant anti-inflammatory effects in
chronic obstructive pulmonary disease at lower plasma
concentrations [3]. Already in the early 90s authors have dem-
onstrated that delivery of sub-bronchodilator doses ofTP (serum
concentration of about 8 μg/ml) significantly attenuated late
asthmatic response, which is inflammatory in nature [7,8].The
steady-state peak serumTP concentration is a function of the
dose, dosing interval, and rate of TP absorption and clear-
ance in the individual patient. Because of marked individual
differences in the rate of TP clearance, the dose required to
achieve a peak serum theophylline concentration in the
10–20 mcg/ml range varies fourfold among patients (e.g.,
400–1600 mg/kg/d in adults <60 y old and 10–36 mg/kg/d in chil-
dren) [9,10]. The dose of TP must then be individualised on the
basis of peak serum concentration measurements in order to
achieve a dose that will provide maximum potential benefit
with minimal risk of adverse effects.
With the aim to reduce these side effects and exploit the
anti-inflammatory benefits of this old drug, there is the po-
tential to reformulate this API for lung delivery as a dry powder
inhaler (DPI). This should open up benefits that would not be
possible using the historical routes of delivery.The authors have
already presented re-purposingTP as pressurised metered dose
(pMDI) solution [11] with good in vitro aerosolisation and cell
results, but the disadvantage of this delivery platform is that
doses are limited to a few micrograms.
Dry powder inhalers have many benefits over other lung
drug delivery platforms, such as pMDIs or nebulisers.They can
deliver high doses, have longer stability due to their solid state,
absence of cold chain storage during transport, high patient
compliance, shorter delivery times, lack of propellants and
absence of the need of patient coordination when the API is
delivered [12–14].
It is a common strategy to include lubricants or surfactants
in an inhalable formulation to improve aerosol performance
[15], reduce powder adhesion to inhaler device [16] and cap-
sules or blisters [17,18]. Common lubricants or surfactants
usually include trileucine, leucine and cyclodextrin [15]. Fur-
thermore, lipophilic components, such as cholesterol and
phospholipid [19], have also been utilised to achieve the above-
mentioned purposes.
Sodium stearate is the sodium salt of stearic acid with a
hydrophobic chain of 18 carbons. Due to its lipophilic nature,
it has been used as a lipophilic adjunct in the formulation of
inhalable aerosols to promote microparticle aerosolisation and
also formulation resistance to environmental humidity [19]. For
example, a previous study has demonstrated that the addition
of a small amount of sodium stearate (1%, w/w) significantly
improves the aerosol performance of tobramycin spray-dried
powders [19].
A review of the literature suggests only few have engineered
TP as a DPI for lung delivery. In 1994, Raeburn andWoodman
[20] showed thatTP could be delivered intra-tracheally to guinea
pigs via DPI, and investigated bronchospasm, inflammation and
airway microvascular leakage. In 2011, Salem et al. [21] pre-
sented nanoparticles of TP for DPI delivery with a view to
enhance the dissolution rate since TP is relatively insoluble in
water. More recently, in 2013, Alhalaweh et al. [22] manufac-
tured of a series of TP co-crystals, with and without excipients
or other APIs, using spray drying as a particle engineering ap-
proach.Their findings produced SD-TP particles. Both the 2011
and 2013 manuscripts were focused more on the use of par-
ticle engineering (controlled agglomeration [21] or spray drying
of co-crystals [22]) for inhalation pharmaceutical applica-
tions and not on the actual re-formulation and aerosol
characterisation of TP as a DPI, as studied here. Specifically,
the aim of this manuscript is to present a TP formulation and
to study its optimisation, physico-chemical properties and in-
teraction with lung epithelia using a Calu-3 epithelial cell
model.
2. Materials and methods
Anhydrous theophylline (TP) and sodium stearate were sup-
plied byMP Biomedicals,Australia.Water was purified by reverse
osmosis (MilliQ, Millipore, France). All solvents used were of
analytical grade and were supplied by Chemsupply (Victoria,
Australia). All sterile culture plastic ware was supplied by
Sarstedt (Adelaide, Australia).
2.1. Particle production
Solutions of TP for spray drying were prepared by mixing equal
volumes of individually prepared TP aqueous solution (30 °C)
and alcoholic solutions of sodium stearate at various concen-
trations (30 °C). The total solid content was maintained at
20 mg/ml and the ratio of sodium stearate to TP was varied.
Sodium stearate weight fractions of 0%, 0.5%, 1.0% and 1.5%
w/w, respectively, based onTP mass were used for spray drying
[19]. Solutions were spray dried using a Büchi B-290 spray dryer
(Büchi Mini Spray Dryer B-191, Flawil, Switzerland) under the
following conditions: inlet temperature 100 °C,measured outlet
temperature 48 °C, solution feed rate 40 ml/min, aspirator rate
100% and atomising airflow 700 l/h.
2.2. Scanning electron microscopy
The morphology of the spray dried TP microparticles contain-
ing various weight fractions of sodium stearate was studied
using a scanning electron microscope (JEOL-6000,Tokyo, Japan)
at 5 kV.TP raw material and spray-dried samples were depos-
ited onto double-sided adhesive carbon tape, mounted to
aluminium stubs and sputter-coated with gold at a coating
thickness of 15 nm prior to imaging.
2.3. Thermal analysis of TP
The thermal response of TP raw material and spray dried
formulations were analysed using differential scanning calo-
rimetry (DSC, model 823e, Mettler Toledo International Inc.,
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Schwerzenbach, Switzerland) at a heating rate of 10 °C/min
between 25 °C and 300 °C. Samples (ca. 5–8 mg) were loaded
and crimp-sealed in 40 μl aluminium sample pans and the
lids pierced to ensure constant pressure. Measurements were
conducted under an inert gas stream (N2, 25 cm3/min).
Thermogravimetric analysis (TGA) was conducted using aTGA
(Mettler-Toledo AG, Schwerzenbach, Switzerland). In brief, ap-
proximately 20 mg of TP raw material and each spray dried
formulation were loaded and analysed at a heating rate of
10 °C/min from 25 °C to 200 °C under an inert gas stream (N2,
25 cm3/min) and the sample weight change (%) recorded.
2.4. Dynamic vapour sorption
The moisture sorption characteristic of spray-dried TP was as-
sessed using dynamic vapour sorption (DVS Intrinsic, Surface
Measurement Systems Limited, London, UK). Approximately
15 mg of spray-dried samples were loaded onto the stainless
steel sample pan and dried at 0% relative humidity (RH) prior
to analysis. The loaded samples were exposed to one 0~90%
RH cycle at 25 °C with 10% RH increment. Equilibrium of mois-
ture sorption was determined by a change inmass-to-time ratio
(dm/dt) of 0.0002%min−1.The data were presented as the sample
mass change (%) over the investigated RH range.
2.5. In vitro aerosol performance analysis
The in vitro aerosol performance of theTP DPI formulations was
determined using a multi-stage liquid impinger (MSLI) (Ap-
paratus A, European Pharmacopoeia, Chapter 2.9.18) (Westech
Scientific Instruments, Bedfordshire, UK) using a RS01® DPI
high-resistance device (Plastiape S.p.A, Osnago-Lecco, Italy).The
flow rate through the MSLI was controlled using a rotary vein
pump and solenoid valve timer (Westech Scientific Instru-
ments, Bedfordshire, UK) set to 60 l/min using a TSI flow-
meter (model 4040,TSI Instruments, MN, US). Deionised water
(20 ml) was accurately added to each MSLI collection stage as
particle recovery and rinsing solution.
A 5 ± 0.2 mg aliquot of spray-driedTP formulations were pre-
loaded into Size 3 hard gelatin capsules (Capsugel, Sydney,
Australia) and placed in the chamber of the inhaler device.The
device was fitted into a silicon mouthpiece adapter, which was
connected to the MSLI equipped with a US Pharmacopoeia
throat. The formulation was actuated at the above men-
tioned flow rate over a four-second period. After actuation, the
capsule, device andmouthpiece adaptor were thoroughly rinsed
with 5 ml deionised water. All the stages were rinsed with
deionised water into suitable volumetric flasks for chemical
quantification. Each formulation was tested in triplicate.
2.6. Calu-3 cell culture
Passages 37–41 of Calu-3 cells (HTB-55) (American Type Cell
Culture Collection (ATTC), Rockville, USA) were grown in com-
plete Dulbecco’s Modified Eagle’s medium: F-12 (Sigma-
Aldrich, Sydney, Australia) and propagated as described
previously [23]. In order to establish the air–liquid interface
model, cells were seeded onto Snapwell® polyester inserts
(0.4 μmpore size, 1.12 cm2 surface area) (Corning Costar, Lowell,
MA, USA) at a density of 5 × 105 cells/cm2 and the monolayers
were allowed to differentiate under air-interface for 14 d.This
period of time in culture was selected based on the study by
Haghi et al. [24] that determined the optimum time in culture
for Calu-3 cells to form tight junctions and produce mucus in
culture.
2.7. Cell integrated modified ACI assessment of TP drug
deposition and transport
The novel integrated modifiedAndersen cascade impactor (ACI)
as described by Haghi et al. [24] was used to assess TP drug
deposition and uptake across the Calu-3 epithelial cells. Four-
teen days post seeding, the Snapwells, containing Calu-3 cells
at the air-interface configuration, were placed on stage 4 of the
ACI (aerodynamic cut-off diameter 2.1–3.3 μm). After particle
deposition, the inserts were transferred to a 6 well plate con-
taining 800 μl of Hank’s balanced salt solution (HBSS)
(Invitrogen, Sydney, Australia) and returned to the incubator.
Samples (100 μl) were taken at 30, 60, 120 and 180 min from
the basal chamber and TP content was analysed using HPLC.
After the final sample was taken, the surface of the Calu-3 cells
was washed with buffer and collected for analysis of residual
apical drug.
To confirm barrier integrity of Calu-3 cells before and after
TP deposition, the transepithelial electrical measurement (TEER)
was performed using an EVOM Voltohmmeter (World Preci-
sion Instruments, FL, USA) with STX-2 chopstick electrodes.
The measured TEER in control Snapwells and before TP depo-
sition was 521 ± 74 ohm·cm2. Following transport studies
(180 min) the cell surface was washed with PBS buffer and the
TEER measured at 458 ± 39 ohm·cm2.
Finally, to quantify the TP retained in the cells, Calu-3 cells
were harvested and lysed using CellLytic TM M Cell Lysis reagent
(Sigma-Aldrich, Sydney, Australia) with 1% (v/v) protease in-
hibitor cocktail (Sigma-Aldrich, Sydney, Australia) according to
the method described previously [23].This method allowed for
the calculation of the total drug deposited by adding the amount
of TP transported, retained in the cells and remaining on the
surface of the epithelial cells.
2.8. High performance liquid chromatography
The quantification of drug from the MSLI and cell based studies
was conducted by high performance liquid chromatography
(HPLC).A Shimadzu HPLC system consisting of a LC20AT pump,
a SIL20AHT autosampler and an SPD-20A UV-VIS detector
(Shimadzu, Sydney, Australia) was used. Samples were in-
jected into a reverse phase C18 column (4.6 × 150 mm and 5 μm,
XBridge™ Shield, Waters, USA) with 55% (v/v) methanol/
water mobile phase at a flow rate of 1 ml/min. The detection
wavelength was 275 nm and injection volume was 100 μl. The
standard solutions were prepared daily and the linearity of stan-
dard solutions in the concentration of 0.01~100 μg/ml was
confirmed with an R2 value ≥ 0.999.
2.9. Statistical analysis
All results are expressed as mean ± standard deviation (SD)
of at least three separate determinants. The results were
analysed using one-way ANOVA followed by post-hoc multiple
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comparisons. Differences were deemed significant for P ≤ 0.05.
Unless otherwise stated, data are represented in terms of mean
and standard deviation.
3. Results and discussion
In the current study,we developed and optimisedTP dry powder
formulation by spray drying for pulmonary delivery using
sodium stearate as lipophilic adjunct. Four batches ofTP powder
with/without sodium stearate were produced. All batches
showed a yield of approximately 60%~73%. The collected
powders were evaluated in terms of surface morphology,
physico-chemical properties, aerodynamic characteristics, and
transport rate across Calu-3 epithelial cell monolayer.
3.1. Particle morphology
The morphology of spray dried TP particles by SEM is shown
in Fig. 1. As seen in Fig. 1A, particles of TP raw material pos-
sessed elongated surface morphology. Spray-dried TP was
spherical with coral-like surface morphology (Fig. 1B). With
the addition of 0.5% and 1.5% (w/w) sodium stearate, co-
spray dried particles lost the spherical morphology with the
presence of crystal-like protrusions (Fig. 1C) and clusters (Fig. 1E).
A previous study suggested that the final distribution of each
solute component in a binary aqueous system during the spray
drying process was dependent on molecular structures of in-
dividual solutes and their relative molecular mass [19]. Sodium
stearate is used as a lipophilic adjunct in the current study,
having a lower aqueous solubility than that of TP [25,26]. Sub-
sequently, during the drying process, sodium stearate molecules
may tend to move toward the air–liquid interface, depositing
at the surface of a dried particle. Therefore, uneven solute
transport rate from the inner core to 2the surface of a drying
droplet may occur [27], resulting in different crystallisation
rates of individual components under certain drying condi-
tions [28]. Furthermore, a suitable weight fraction ratio between
the individual solute components in the binary system is also
required to balance the crystallisation rates of each compo-
nent in order to achieve the particle morphology suitable for
inhalation delivery purpose [29]. In general, 1.0% w/w pro-
duced the most suitable (spherical and homogeneous)
morphology (Fig. 1D).
3.2. Physico-chemical characterisation
The thermal responses of TP raw material and spray-dried for-
mulations using DSC are shown in Fig. 2. Sodium stearate
produced no obvious effects on the thermal behaviours of the
produced formulations, since weight fractions of sodium stea-
rate in the dried particulate systems were considerably low.
Fig. 1 – Scanning electron micrographs of theophylline raw material (A) and spray-dried formulation containing 0% (B), 0.5%
(C), 1.0% (D) and 1.5% (E) sodium stearate.
Fig. 2 – Thermograms of theophylline raw material and
spray-dried formulations.
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All samples subject to DSC analysis showed an endothermic
peak at approximately 271 °C, corresponding toTPmelting event
[30,31]. No exothermic events were observed in the tempera-
ture region below 150 °C, indicating all samples to be crystalline.
Furthermore, there was no endothermic response noted at
70~90 °C region for TP raw material and weight loss data from
TGAwere shown to beminimum (<0.01%,w/w; data not shown),
confirming the anhydrous form. Weight loss analysis of all
spray-dried formulations upon heating suggested prepared for-
mulations to be anhydrate with an average weight loss of
<0.1% (w/w).
To investigate the relative solid-state stability of the spray
dried and co-spray dried powders, the influence of humidity
on moisture sorption was performed. Representative mois-
ture sorption isotherms for the prepared formulations as a
function of relative humidity (%) are shown in Fig. 3. As seen,
all formulations showed minimal weight gain of 0.4~0.6%
between 0% and 90% RH.Theophylline is known to exist in three
different solid-state forms, i.e. anhydrate, monohydrate and a
metastable dehydrate [32]. It has been reported that anhy-
drous TP converts to monohydrate when exposed to >80%
relative humidity and the subsequent compound dehydrates
at low RH (usually <20%) [33]. The dehydration of TP monohy-
drate is considered as a two-step process consisting of
dehydration and evaporation of crystal water [33]. As shown
in Fig. 3A, theTP spray-dried formulation showed a small weight
gain of 0.14% (w/w) after desorption. Previous research has dem-
onstrated that TP monohydrate may transit to a metastable
dehydrate during drying [34]. Therefore, hysteresis in transi-
tion from metastable dehydrate to anhydrous form and
incomplete evaporation of water molecules in the crystal lattice
during the desorption cycle may contribute to the observed
weight gain. Fig. 4 shows the hysteresis of mass change between
sorption and desorption cycles in the investigated RH range.
As seen, the TP powder (i.e. 0% sodium stearate) consistently
showed positive hysteresis values between 10% and 80% RH
with a decreasing trend when RH was below 50%, also sug-
gesting the incomplete compound phase transition in the
monohydrate dehydration process [34].
Fig. 3B and D shows the representative moisture sorption
isothermsofTP particles containing 0.5%and 1.5% (w/w) sodium
stearate, respectively.As seen,TPmicroparticles containing 0.5%
and 1.5% (w/w) sodium stearate had increased desorption rates
between 30% and 40% RH compared to 0% and 1.0% formula-
tions. Previous study with NaSt in a range from 0 to 2% w/w
[19] suggested micelle formation in the co-spray dried par-
ticleswhen the concentration of sodiumstearate in an atomised
droplet was above its critical micelle concentration, between
4.0 × 10−4 and 5.6 × 10−4 M [35,36], with a parabolic dependence
observed for NaStwith a peak around the 1% content of sodium
stearate. Positive hysteresis values for 0.5% and 1.5% formu-
lations canbe found in Fig. 4 in the 30%~40%RH range.Therefore,
Fig. 3 – Dynamic vapour sorption isotherms of spray-dried theophylline and co-spray dried theophylline containing
different concentrations of sodium stearate.
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it can be speculated that inclusion of sodium stearate in the
particulate systems at low (0.5%, w/w) and high (1.5%, w/w)
concentrations may have a great influence on crystal lattice
repacking during TP monohydrate–anhydrate transition, re-
sulting in observed abnormalities in the drying cycle.TP particles
containing 1.0% (w/w) sodium stearate generally followed the
sorption/desorption profile of crystallinematerials [37] (Fig. 3C)
with minimal hysteresis in both cycles [19].
3.2.1. Impaction study and aerosolisation performance
Prepared DPI formulations were subjected to in vitro cascade
impaction test via a multi-stage liquid impinger (MSLI) in order
to evaluate their aerodynamic diameters and aerosol perfor-
mances. Table 1 summarises the mass median aerodynamic
diameters (MMAD) and geometric standard deviation (GSD) of
tested formulations.The physical diameter of the resulting spray
dried particles is governed by the solute concentration in a
droplet once other parameters (e.g. atomised droplet diam-
eter, drying temperature and solvent, etc.) are fixed [38,39].This
can potentially explain the similar MMADs and GSDs of pre-
pared formulations in the current study, since overall solute
concentration wasmaintained at the same level (20 mg/ml) and
no other parameter varied [40,41].
Besides size, morphology is also one of the key factors gov-
erning the aerodynamic performance of a given particle [28].
Statistical analysis showed no significant difference in aero-
dynamic size among the formulations containing 0%, 0.5% and
1.0% (w/w) sodium stearate, possibly due to their sphere-like
morphological characteristics. However, significant statistical
difference was observed between 1.0% and 1.5% (w/w) formu-
lations. Since the MMAD of 1.5% (w/w) formulation was
significantly lower than that of 1.0% (w/w) formulation, it can
be speculated that the 1.5% (w/w) particle formulation may
undergo fracture [42] during the aerosolisation process, since
majority of them possessed needle-like surface morphology
(Fig. 1E).
Mass deposition of each formulation delivered via RS01 dry
powder inhaler on each MSLI stage is expressed as the per-
centage of the total mass recovered (>95% of loaded dose) and
shown in Fig. 5. To further analyse the aerosol performance,
the emptying efficiency and aerosol performance parameters
are shown in Fig. 6. Fine particles were deemed as particles with
an aerodynamic diameter ≤6.8 μm (i.e. MSLI stage 3 to filter)
and their fractions over loaded dose and emitted dose calcu-
lated as fine particle fractions of loaded and emitted doses (FPFLD
and FPFED, respectively).
As seen in Fig. 5, the 0% sodium stearate formulation had
the highest powder retention in the capsule after dispersion
under the pharmacopeia testing condition (i.e. 60 l/min over
a four-second period), with 41.16 ± 0.21% of recovered mass re-
tained within the capsule. Such rate was significantly lower
for other formulations: 4.99 ± 1.61%, 6.35 ± 1.3% and 4.51 ± 0.81%
for 0.5%, 1.0% and 1.5% formulation, respectively. As a result,
emptying efficiency of TP spray-dried formulation was signifi-
cantly lower with approximately 42% mass emitted compared
to ~73% for co-spray dried formulations. The 0% formulation
showed an induction port deposition of 13.38 ± 0.12%, signifi-
cantly lower than the 20~30% obtained for the rest of prepared
formulations (P < 0.05).
Fig. 4 – Hysteresis of mass change over the investigated
relative humidity range of moisture sorption study.
Table 1 – Mass median aerodynamic diameter (MMAD)
and geometric standard deviation (GSD) of theophylline
particles containing different weight fractions of sodium
stearate (n = 3 ± SD).
Formulation
(sodium stearate %, w/w)
MMAD (μm) GSD
0% 2.88 ± 0.12 2.44 ± 0.13
0.5% 3.04 ± 0.04 2.32 ± 0.14
1.0% 3.31 ± 0.32 2.04 ± 0.11
1.5% 2.71 ± 0.12 2.35 ± 0.09
Fig. 5 – Stage mass deposition profiles of theophylline DPI
formulations (n = 3 ± SD).
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In general, the majority of post-throat aerosols deposited
in the aerodynamic size region ≤6.8 μm.The addition of sodium
stearate in the formulation influenced the FPF of emitted aerosol
cloud in a positive manner (Fig. 6). For example, the FPFLD sig-
nificantly increased from 21.49 ± 0.05% to 29.70 ± 2.59% (P < 0.05)
when the weight fraction of sodium stearate was increased from
0% to 1.0% (w/w). This observation is possibly the result of
surface distribution of sodium stearate molecules on the par-
ticles during the spray drying process, consequently reducing
inter-particle cohesion [19]. However, there was no clear linear
correlation between the FPFLD and weight fraction of sodium
stearate in the formulation as demonstrated by Parlati et al.
[19]. Peak FPFLD was observed with 1.0% (w/w) sodium stea-
rate added in the formulation and the difference of FPFLD values
between 0.5% and 1.5% formulations was not significant
(P > 0.05, Fig. 6). As mentioned previously, once the concentra-
tion of sodium stearate reaches the critical micelle
concentration, micelle formation may occur, causing
internalisation of a considerable amount of sodium stearate
and thus insufficient surface counts [19]. The FPFED of sodium
stearate-containing formulations showed a similar trend of FPFLD
(Fig. 6). The FPFED of 0% formulation was approximately 50%,
possibly due to the porous nature of produced particles (Fig. 1);
however, the high capsule retention renders its aerosolisation
efficiency less desirable.
To summarise, all the prepared formulations had similar
aerodynamic diameters and post-induction port distribution
profiles. However,TP formulation containing 1.0% (w/w) sodium
stearate showed the most suitable aerosolisation efficiency.
3.3. In vitro TP transport using a modified ACI and
Calu-3 model
Transport of TP microparticles containing 1% w/w magne-
sium stearate over 180 min is shown in Fig. 7. Results
demonstrated that 56.14 ± 7.62% of the total TP deposited
(13.07 ± 1.69 μg) was transported across the Calu-3 mono-
layer over 180 min following deposition, while 37.05 ± 12.62%
of the depositedTP was retained in the cells.This could be due
to the presence of sodium stearate in the current formula-
tion that could have increased its lipophilicity. Further studies
are currently under investigation to understand this phenom-
enon. In a previous study, where TP was formulated as a
pressurised metered dose inhaler, it was observed that the
amount of drug retained in the cells was negligible, while 97%
of the depositedTP (1.25 ± 0.40 μg) was transported over 180min
of study [11]. In comparison, the current formulation shows
a significantly faster transport rate over 30 min following drug
deposition (~90 ngTP from the pressurisedmetered dose inhaler
vs. ~2.6 μg TP from the DPI formulation), which could indi-
cate higher concentration of TP at the site of action (A3
Adenosine receptors located on the smoothmuscle cells) 30min
following deposition, potentially resulting in faster onset of
action.
4. Conclusions
In the current investigation, a TP dry powder inhaler formu-
lation containing 1.0% (w/w) sodium stearate as lipophilic
adjunct was successfully developed. The formulation showed
suitable physico-chemical and aerodynamic properties for lung
delivery, as confirmed by the morphology and aerosol perfor-
mance studies. Cell studies confirmed TP DPI delivered on
Calu-3 cells to be able to transport across epithelial cells to reach
its site of action.
The formulation shows potential for the repurposing of TP
to treat asthma-related lung diseases via pulmonary route
instead of the classical oral route. Future research interest will
be investigating this formulation in vivo.
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